Artelo Biosciences, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ARTL Nasdaq 2834 www.artelobio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artelo Biosciences, Inc.

Sector Update: Health Care Stocks Advance Monday Afternoon - Jun 30th, 2025 11:49 am
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain - Jun 30th, 2025 5:45 am
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing - Jun 26th, 2025 6:00 am
Artelo Biosciences Announces Reverse Stock Split - Jun 11th, 2025 6:30 am
Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study - Jun 5th, 2025 7:00 am
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression - Jun 2nd, 2025 7:00 am
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results - May 13th, 2025 6:00 am
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis - Apr 28th, 2025 6:45 am
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 - Mar 31st, 2025 6:30 am
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results - Mar 3rd, 2025 6:00 am
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - Feb 14th, 2025 7:00 am
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland - Feb 11th, 2025 7:00 am
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - Jan 13th, 2025 7:00 am
Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia - Dec 10th, 2024 7:43 am
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia - Dec 9th, 2024 7:15 am
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit - Nov 18th, 2024 6:30 am
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium - Nov 13th, 2024 6:30 am
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 12th, 2024 6:00 am
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program - Nov 5th, 2024 6:30 am
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th - Oct 9th, 2024 7:00 am